Compare Stocks

National Research (($NRC)) has held its Q3 earnings call. Read on for the main highlights of the call. NRC Health’s earnings call struck a broadly positive tone, led by 11%

Citizens raised the firm’s price target on NRC Health (NRC) to $27 from $26 and keeps an Outperform rating on the shares. Following the “strong” Q3 results, Citizens tells investors

Reports Q3 revenue $38.4M, one estimate $35.8M. “We delivered a strong third quarter, with revenue up 11% year-over-year and sequential margin expansion,” said Trent Green, CEO of NRC Health (NRC).

National Research ( ($NRC) ) has provided an update. On October 14, 2026, NRC Health’s board of directors appointed Chief Executive Officer Trent Green to serve concurrently as the company’s

Resideo Technologies (REZI) announced that Shane Harrison has been appointed as Resideo’s CFO, effective September 1. He joins Resideo from NRC Health (NRC), a publicly traded healthcare technology and analytics

National Research ( ($NRC) ) has issued an announcement. On August 7, 2026, NRC Health announced that its Chief Financial Officer and principal financial officer, Shane Harrison, has tendered his

Citizens raised the firm’s price target on NRC Health (NRC) to $26 from $23 and keeps an Outperform rating on the shares. NRC Health delivered a modest Q2 beat, with

Reports Q2 revenue $35.4M vs. $34.0M last year. “Our second quarter was a success on many fronts, including double-digit TRCV growth over the prior year, strong go-to-market and solutions delivery

National Research ( ($NRC) ) has shared an announcement. At its June 23, 2026 annual meeting, National Research Corporation shareholders approved a series of governance changes, including eliminating certain supermajority

Citizens analyst Constantine Davides initiated coverage of NRC Health (NRC) with an Outperform rating and $23 price target NRC is a leading provider of experience management solutions sold into the